N-(3-(methylcarbamoyl)phenyl)-4-(o-tolyloxy)piperidine-1-carboxamide | 1058702-70-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-(methylcarbamoyl)phenyl)-4-(o-tolyloxy)piperidine-1-carboxamide
• 英文别名: N-[3-(methylcarbamoyl)phenyl]-4-(2-methylphenoxy)piperidine-1-carboxamide
• CAS: 1058702-70-7
• 化学式: C₂₁H₂₅N₃O₃
• 分子量: 367.448
• InChiKey: AQGBQLJURMHFFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(2-甲基苯氧基)哌啶盐酸盐 、 3-isocyanato-N-methylbenzamide 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 N-(3-(methylcarbamoyl)phenyl)-4-(o-tolyloxy)piperidine-1-carboxamide
  参考文献：
  名称：

  Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors

  摘要：

  A series of structurally novel stearoyl-CoA desaturase1 (SCD1) inhibitors has been identified via molecular scaffold manipulation. Preliminary structure-activity relationship (SAR) studies led to the discovery of potent, and orally bioavailable piperidine-aryl urea-based SCD1 inhibitors. 4-(2-Chlorophenoxy)-N-[3-(methyl carbamoyl)phenyl]piperidine-1-carboxamide 4c exhibited robust in vivo activity with dose-dependent desaturation index lowering effects. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.088

文献信息

• [EN] METHODS OF TREATING SARS-COV-2 INFECTION USING INHIBITORS OF LIPOGENESIS<br/>[FR] MÉTHODES DE TRAITEMENT D'UNE INFECTION PAR LE SARS-COV-2 À L'AIDE D'INHIBITEURS DE LA LIPOGENÈSE
  申请人：UNIV CALIFORNIA

  公开号：WO2022005871A1

  公开（公告）日：2022-01-06

  The present disclosure provides methods of treating a SARS-CoV-2 infection in a patient infected with SARS-CoV-2. The present disclosure provides pharmaceutical compositions comprising an inhibitor of lipogenesis, optionally, in combination with an RdRp inhibitor and/or an anti-inflammatory agent.